Robert S Rosenson

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. doi request reprint Treatment with aspirin and dipyridamole is more effective than aspirin in reducing low shear blood viscosity
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan 48106, USA
    Microcirculation 15:615-20. 2008
  2. ncbi request reprint Measure for measure--sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy
    Robert S Rosenson
    University of Michigan Medical Center, Ann Arbor, MI, USA
    Nat Clin Pract Endocrinol Metab 3:72-3. 2007
  3. doi request reprint Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Domino s Farms, 24 Frank Lloyd Wright Drive, Lobby A, Ann Arbor, MI 48106 0736, USA
    Atherosclerosis 198:381-8. 2008
  4. doi request reprint Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI 48106 0636, USA
    Am Heart J 155:499.e9-16. 2008
  5. pmc Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study
    Robert S Rosenson
    University of Michigan, Ann Arbor, Michigan, USA
    Diabetes Care 32:1087-91. 2009
  6. doi request reprint Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients
    Robert S Rosenson
    Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Obesity (Silver Spring) 17:504-9. 2009
  7. doi request reprint Fenofibrate: treatment of hyperlipidemia and beyond
    Robert S Rosenson
    Lipoprotein Disorders and Clinical Atherosclerosis Research, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
    Expert Rev Cardiovasc Ther 6:1319-30. 2008
  8. doi request reprint Lipoprotein associated phospholipase A2 inhibition reduces generation of oxidized fatty acids: Lp-LPA2 reduces oxidized fatty acids
    Robert S Rosenson
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA
    Cardiovasc Drugs Ther 22:55-8. 2008
  9. doi request reprint Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events
    Melvyn Rubenfire
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Mich 48106, USA
    Am J Med 123:892-8. 2010
  10. doi request reprint Biomarkers, atherosclerosis and cardiovascular events
    Robert S Rosenson
    Department of Medicine, University of Michigan, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Drive, Lobby A, Ann Arbor, MI 48106, USA
    Expert Rev Cardiovasc Ther 6:619-22. 2008

Detail Information

Publications59

  1. doi request reprint Treatment with aspirin and dipyridamole is more effective than aspirin in reducing low shear blood viscosity
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan 48106, USA
    Microcirculation 15:615-20. 2008
    ..Investigate effects of aspirin/dipyridamole and aspirin on blood viscosity (BV) in subjects with hyperhomocystememia (>14 micromol/L) and stable cardiovascular disease (CVD) or >or= 20% risk for CVD were the aims of this study...
  2. ncbi request reprint Measure for measure--sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy
    Robert S Rosenson
    University of Michigan Medical Center, Ann Arbor, MI, USA
    Nat Clin Pract Endocrinol Metab 3:72-3. 2007
  3. doi request reprint Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Domino s Farms, 24 Frank Lloyd Wright Drive, Lobby A, Ann Arbor, MI 48106 0736, USA
    Atherosclerosis 198:381-8. 2008
    ..To examine the effects of fenofibrate (160mg/d) therapy on fasting and postprandial cytokine production in subjects with metabolic syndrome and hypertriglyceridemia...
  4. doi request reprint Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI 48106 0636, USA
    Am Heart J 155:499.e9-16. 2008
    ..Fenofibrate reduces Lp-PLA2 mass; however, it remains unknown whether the anti-inflammatory effects of fenofibrate are related to changes in LDL subclasses...
  5. pmc Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study
    Robert S Rosenson
    University of Michigan, Ann Arbor, Michigan, USA
    Diabetes Care 32:1087-91. 2009
    ..Changes in lipoprotein particle concentration may predict the risk of coronary heart disease more accurately than lipoprotein cholesterol levels...
  6. doi request reprint Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients
    Robert S Rosenson
    Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Obesity (Silver Spring) 17:504-9. 2009
    ..Changes in adiponectin were significantly and inversely associated with changes in multiple inflammatory markers. These data suggest that adiponectin may contribute to the anti-inflammatory effects of fenofibrate...
  7. doi request reprint Fenofibrate: treatment of hyperlipidemia and beyond
    Robert S Rosenson
    Lipoprotein Disorders and Clinical Atherosclerosis Research, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
    Expert Rev Cardiovasc Ther 6:1319-30. 2008
    ..The clinical significance of combination therapy with fenofibrate and a statin to macrovascular and microvascular risk is being evaluated in a large outcomes study...
  8. doi request reprint Lipoprotein associated phospholipase A2 inhibition reduces generation of oxidized fatty acids: Lp-LPA2 reduces oxidized fatty acids
    Robert S Rosenson
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA
    Cardiovasc Drugs Ther 22:55-8. 2008
    ..Through the use of a selective inhibitor of Lp-PLA(2) (SB-677116), we investigated whether Lp-PLA(2) participates in the ex vivo generation of oxidized fatty acids (ox-FA)...
  9. doi request reprint Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events
    Melvyn Rubenfire
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Mich 48106, USA
    Am J Med 123:892-8. 2010
    ....
  10. doi request reprint Biomarkers, atherosclerosis and cardiovascular events
    Robert S Rosenson
    Department of Medicine, University of Michigan, Division of Cardiovascular Medicine, 24 Frank Lloyd Wright Drive, Lobby A, Ann Arbor, MI 48106, USA
    Expert Rev Cardiovasc Ther 6:619-22. 2008
    ..It was attended by nearly 30,000 participants from around the world. The conference was highlighted by the presentation of 13 late-breaking clinical trials and 13 late-breaking abstracts...
  11. doi request reprint Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
    Lancet 373:649-58. 2009
    ..We examined the effects of an sPLA(2) inhibitor on enzyme concentration and on plasma lipoproteins and inflammatory biomarkers in patients with coronary heart disease...
  12. ncbi request reprint Effects of peroxisome proliferator-activated receptors on lipoprotein metabolism and glucose control in type 2 diabetes mellitus
    Robert S Rosenson
    Division of Cardiovascular Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan 48106 0363, USA
    Am J Cardiol 99:96B-104B. 2007
    ..Future studies of PPAR-gamma agonists or dual PPAR-alpha/gamma agonists will require further delineation of the risk profile to avoid adverse outcomes in susceptible patients...
  13. ncbi request reprint Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome
    Robert S Rosenson
    Division of Cardiovascular Medicine, University of Michigan, Domino s Farms, 24 Frank Lloyd Wright Dr, Lobby A, Ann Arbor, MI 48106 0736, USA
    Diabetes Care 30:1945-51. 2007
    ..The aim of this study was to determine the effects of fenofibrate (160 mg/day) on fasting and postprandial lipoproteins, oxidized fatty acids, and inflammatory mediators in subjects with hypertriglyceridemia and the metabolic syndrome...
  14. doi request reprint Adenosine transport, erythrocyte deformability and microvascular dysfunction: an unrecognized potential role for dipyridamole therapy
    Jignesh Bhavsar
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, USA
    Clin Hemorheol Microcirc 44:193-205. 2010
    ..In addition, it has anti-oxidant and anti-inflammatory properties that provide protection to the microvasculature. This review discusses the potential role for dipyridamole therapy in the treatment of microvascular dysfunction...
  15. pmc Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates
    Kwang Kon Koh
    Division of Cardiology, Gil Heart Center, Gachon Medical School, Incheon, Republic of Korea
    Int J Cardiol 124:149-59. 2008
    ..When statins are combined with gemfibrozil therapy, this is more likely to be accompanied by myopathy. However, this limitation is not observed when fenofibrate, bezafibrate, or ciprofibrate are used in combination therapy...
  16. ncbi request reprint New approaches in the intensive management of cardiovascular risk in the metabolic syndrome
    Robert S Rosenson
    Department of Medicine, Northwestern University, Feinberg School of Medicine, USA
    Curr Probl Cardiol 30:241-79. 2005
    ..A multifaceted approach to risk factor management for the metabolic syndrome will have benefits for prevention of type 2 diabetes and cardiovascular disease...
  17. ncbi request reprint Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets
    Robert S Rosenson
    Postgrad Med 117:17-20, 23-7. 2005
    ..He also highlights major findings from recent clinical trials to explore statin therapy and other treatment strategies for lowering lipoprotein levels in this patient population...
  18. ncbi request reprint Antiatherothrombotic effects of nicotinic acid
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 East Huron Street, Galter Pavilion 11 120, Chicago, IL 60612, USA
    Atherosclerosis 171:87-96. 2003
    ..By preserving glycolysis during periods of ischemia and improving subendocardial blood flow during reperfusion, niacin can improve the functional recovery of the myocardium...
  19. ncbi request reprint Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Galter Pavilion 11 120, 201 East Huron Street, Chicago, IL 60611, USA
    Curr Opin Cardiol 20:313-7. 2005
    ..Discuss the contribution of low-density lipoprotein subclass abnormalities to cardiovascular risk among individuals with low high-density lipoprotein cholesterol levels...
  20. ncbi request reprint Colesevelam HCl reduces LDL particle number and increases LDL size in hypercholesterolemia
    Robert S Rosenson
    Preventive Cardiology Center, Department of Medicine, Division of Cardiology, Northwestern University, The Feinberg School of Medicine, Galter Pavilion, Suite 11 120, 201 East Huron Street, Chicago, IL 60611, USA
    Atherosclerosis 185:327-30. 2006
    ..The effect of colesevelam HCl on LDL particle number and particle size has not been previously published. LDL particle number and particle size were measured by NMR spectroscopy...
  21. ncbi request reprint Short-term reduction in bone markers with high-dose simvastatin
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Departments of Medicine and Preventive Medicine, Northwestern University, Feinberg School of Medicine, 301 E Huron Street, Galter Pavilion, Chicago, IL 60611, USA
    Osteoporos Int 16:1272-6. 2005
    ..Short-term use of high-dose simvastatin lowers the level of the serum bone marker bone-specific alkaline phosphatase, which suggests the possibility of reduced bone turnover...
  22. ncbi request reprint Assessing risk across the spectrum of patients with the metabolic syndrome
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Am J Cardiol 96:8E-10E. 2005
    ..Risk assessment models for patients with the metabolic syndrome should consider inclusion of LDL particle number, inflammatory markers, and levels of plasminogen activator inhibitor-1...
  23. ncbi request reprint Field of confusion: future prospects for fibrate therapy in cardiovascular disease
    Robert S Rosenson
    Curr Atheroscler Rep 8:219-22. 2006
  24. ncbi request reprint Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study
    Lawrence A Leiter
    Division of Endocrinology and Metabolism, St Michael s Hospital, University of Toronto, Toronto, Canada
    Atherosclerosis 194:e154-64. 2007
    ..Rosuvastatin may therefore improve LDL-C goal achievement in high-risk patients with hypercholesterolemia...
  25. ncbi request reprint Association between reduced low density lipoprotein oxidation and inhibition of monocyte chemoattractant protein-1 production in statin-treated subjects
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Lab Clin Med 145:83-7. 2005
    ..46, P = .0056) in statin-treated subjects. Statin therapy reduced MCP-1 production in the whole blood of human subjects and these changes were correlated with improvement in LDL oxidative resistance...
  26. ncbi request reprint Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial
    James D Otvos
    Department of Biochemistry, North Carolina State University, Raleigh, NC, USA
    Atherosclerosis 160:41-8. 2002
    ....
  27. ncbi request reprint Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day
    Robert S Rosenson
    Department of Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Am J Cardiol 91:878-81. 2003
  28. ncbi request reprint Current overview of statin-induced myopathy
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Med 116:408-16. 2004
    ..Drug-drug interactions may be avoided by selecting a statin that does not share the same metabolic pathway...
  29. ncbi request reprint The rationale for combination therapy
    Robert S Rosenson
    Department of Medicine and Preventive Medicine, Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 90:2K-7K. 2002
    ..This article reviews the rationale for the use of combination therapy in the treatment of dyslipidemia, highlighting management strategies...
  30. ncbi request reprint Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 East Huron Street, Galter Pavilion, Chicago, IL 60611, U S A
    Clin Sci (Lond) 106:215-7. 2004
    ..In contrast with the known effects of oxidized LDL on gene activation of ICAM-1 and VCAM-1, lag times did not correlate with sICAM-1 and sVCAM-1. Statin therapy improved lag times, but has no effect on sICAM-1 or sVCAM-1 levels...
  31. ncbi request reprint Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial
    Scott M Grundy
    The University of Texas Southwestern Medical Center, Room Y3206, 5323 Harry Hines Blvd, Dallas, TX 75390 9052
    Arch Intern Med 162:1568-76. 2002
    ..We evaluated the efficacy and safety of once-daily extended-release (ER) niacin in patients with diabetic dyslipidemia...
  32. ncbi request reprint Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Northwestern University Medical School, Chicago, Illinois, USA
    Am J Cardiol 90:89-94. 2002
    ..01) in the placebo group. These results indicate that levels of various lipoprotein subclasses may provide useful information on CAD risk even if levels of traditional risk factors are known...
  33. ncbi request reprint Statins in atherosclerosis: lipid-lowering agents with antioxidant capabilities
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 E Huron Street, Galter Pavilion, Suite 11 120, Chicago, IL 60611, USA
    Atherosclerosis 173:1-12. 2004
    ..It may be that the ability of statins to limit the oxidation of LDL contributes to their effectiveness at preventing atherosclerotic disease...
  34. ncbi request reprint Therapeutic approaches in the prevention of cardiovascular disease in metabolic syndrome and in patients with type 2 diabetes
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Departments of Medicine and Preventive Medicine, The Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Curr Opin Cardiol 19:480-7. 2004
    ..This article reviews evidence that treatments directed at the individual components of the metabolic syndrome will delay the progression to type 2 diabetes and will reduce the incidence of cardiovascular disease...
  35. ncbi request reprint Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis
    Rukmini Rajagopalan
    Takeda Pharmaceuticals North America, Inc, Lincolnshire, Illinois 60069, USA
    Clin Ther 26:1400-10. 2004
    ..However, concerns have been raised regarding the association between TZD use and a heightened risk for congestive heart failure (CHF)...
  36. ncbi request reprint HDL-C and the diabetic patient: target for therapeutic intervention?
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, 201 East Huron Street, Galter Pavilion Suite 11 120, Chicago, IL 60611, USA
    Diabetes Res Clin Pract 68:S36-42. 2005
    ..Selecting an agent that will increase HDL-C levels, as well as lowering LDL-C levels, may be particularly beneficial in the treatment of patients with the metabolic syndrome and type 2 diabetes...
  37. ncbi request reprint Variations of whole blood viscosity using Rheolog-a new scanning capillary viscometer
    Sihe Wang
    Department of Pathology and Laboratory Medicine, The Feinberg School of Medicine, Northwestern University, 2300 Children s Plaza, Chicago, IL 60614, USA
    Clin Chim Acta 332:79-82. 2003
    ..A new type of viscometer, Rheolog, was designed to overcome the difficulties encountered in WBV measurements using the standard rotational viscometer in a clinical environment...
  38. ncbi request reprint Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action
    Jaime A Davidson
    University of Texas Southwestern Medical School, Dallas, TX, USA
    Ethn Dis 17:568-73. 2007
    ..It is therefore imperative to understand this population's risk of CVD and the most effective and culturally sensitive treatment methods...
  39. ncbi request reprint Avoiding the looming Latino/Hispanic cardiovascular health crisis: a call to action
    Jaime A Davidson
    University of Texas Southwestern Medical School, Dallas, TX, USA
    J Cardiometab Syndr 2:238-43. 2007
    ..A combined effort of health-influencing and health-governing bodies is needed on all levels to address the CVD problem in the Latino/Hispanic population...
  40. ncbi request reprint Effects of hydration on blood rheology
    George A Vlastos
    Lipoprotein and Hemorheology Research Facility, Department of Medicine and Pathology, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
    Clin Hemorheol Microcirc 28:41-9. 2003
    ..The corrected elastic component of blood viscoelasticity increased 90 minutes after hydration (p<0.05). An overnight fast is accompanied by rheological abnormalities that are altered by fluid intake...
  41. ncbi request reprint Hypertriglyceridemia is associated with an elevated blood viscosity Rosenson: triglycerides and blood viscosity
    Robert S Rosenson
    Lipoprotein and Hemorheology Research Facility, Section of Cardiology, Department of Medicine, Rush Presbyterian St Luke s Medical Center, Chicago, IL, USA
    Atherosclerosis 161:433-9. 2002
    ..This study supports an additional mechanism whereby triglycerides may contribute to cardiovascular risk...
  42. ncbi request reprint Elevated soluble tumor necrosis factor receptor levels in non-obese adults with the atherogenic dyslipoproteinemia
    Robert S Rosenson
    Department of Medicine, Division of Cardiology, Preventive Cardiology Center, The Feinberg School of Medicine, Northwestern University, 201 East Huron Street, Galter Pavilion, Suite 11 120, Chicago, IL 60611, USA
    Atherosclerosis 177:77-81. 2004
    ..048). A high level of sTNFRSF1B is a strong marker of the pro-inflammatory state in this sample of male ADL subjects...
  43. ncbi request reprint High-sensitivity C-reactive protein and cardiovascular risk in patients with coronary heart disease
    Robert S Rosenson
    Preventive Cardiology Center, Department of Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA
    Curr Opin Cardiol 17:325-31. 2002
    ....
  44. ncbi request reprint Physicians' interpretation of "class effects": a need for thoughtful re-evaluation
    Harold L Kennedy
    Cardiology Section, Department of Medicine, University of South Florida, Tampa, Florida, USA
    J Am Coll Cardiol 40:19-26. 2002
    ..quot; An appeal is made for physicians to prescribe those pharmaceutical agents with definitive evidence of mortality and morbidity efficacy and safety established by appropriately scaled randomized clinical trials...
  45. ncbi request reprint Effect of methyl testosterone administration on plasma viscosity in postmenopausal women
    Shehzad Basaria
    Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
    Clin Endocrinol (Oxf) 57:209-14. 2002
    ..Recently, there has been a growing interest in the treatment of postmenopausal women with androgens. However, no data are available on plasma viscosity and fibrinogen levels in postmenopausal women on combined oestrogen/androgen therapy...
  46. ncbi request reprint Statins and sepsis: multiple modifications at multiple levels
    Marius Terblanche
    Department of Critical Care Medicine, St Thomas Hospital, London, UK
    Lancet Infect Dis 7:358-68. 2007
    ..This work establishes the biological plausibility needed for future trials of statins in critical illness...
  47. ncbi request reprint Targeting dyslipidemia--the key to CHD risk reduction in the diabetic population?
    D John Betteridge
    Endocrinology and Metabolism, Department of Medicine, University College London Medical School, London, UK
    Diabetes Res Clin Pract 68:S1-2. 2005
  48. ncbi request reprint Comparison of two whole blood viscometers: implications for cardiovascular and thrombosis research
    Robert S Rosenson
    Thromb Haemost 92:225-6. 2004
  49. ncbi request reprint Atherosclerotic Vascular Disease Conference: Writing Group II: risk factors
    Sidney C Smith
    Circulation 109:2613-6. 2004
  50. ncbi request reprint Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status
    Sridevi Devaraj
    Laboratory for Atherosclerosis and Metabolic Research, University of California Davis Medical Center, 4365 Second Avenue, Room 3000, Sacramento CA 95817, USA
    Endocrinol Metab Clin North Am 33:431-53, table of contents. 2004
    ..Elevated von Willebrand's factor and factor VIII levels aggregate with indicators of endothelial injury,whereas vitamin K-dependent coagulation proteins correlate with triglyceride levels...
  51. ncbi request reprint Low HDL-C: a secondary target of dyslipidemia therapy
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, Chicago, Ill 60611, USA r rosenson northwestern edu
    Am J Med 118:1067-77. 2005
    ..Although lowering LDL-C remains the primary target of lipid-modifying therapy, dyslipidemia therapies that are efficacious for both LDL-C reduction and raising HDL-C might offer further improvements in CHD risk reduction...
  52. ncbi request reprint Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, Chicago, IL, USA
    Am Heart J 151:556-63. 2006
    ..Extending statin therapy to patients with low levels of HDL-C but with LDL-C levels below target may have benefits for cardiovascular disease reduction in these patients...
  53. ncbi request reprint Statins: panacea for sepsis?
    Marius Terblanche
    Interdepartmental Division of Critical Care Medicine, Sunnybrook and Women s College Health Science Centre, Toronto, Canada
    Lancet Infect Dis 6:242-8. 2006
    ....
  54. ncbi request reprint An assessment of statin safety by muscle experts
    Paul D Thompson
    Division of Cardiology, Hartford Hospital, Hartford, Connecticut 06102, USA
    Am J Cardiol 97:69C-76C. 2006
    ..The panel was composed of a clinical cardiologist, an exercise physiologist and skeletal muscle expert, and an expert in preventive cardiology who also examined skeletal muscle complications of statin use...
  55. ncbi request reprint Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia
    Robert S Rosenson
    Preventive Cardiology Center, Northwestern University, The Feinberg School of Medicine, Chicago, IL 60611, USA
    Expert Rev Cardiovasc Ther 1:495-505. 2003
    ..Rosuvastatin is well tolerated, with a safety profile comparable with that of other currently available statins...
  56. ncbi request reprint Statin use in acute coronary syndromes: cellular mechanisms and clinical evidence
    Robert S Rosenson
    Preventive Cardiology Center, Division of Cardiology, Department of Medicine, Northwestern University, The Feinberg School of Medicine, Chicago, IL 60611, USA
    Curr Opin Lipidol 13:625-30. 2002
    ..Review the cellular mechanisms and clinical evidence for the use of statins in patients with unstable coronary syndromes...
  57. ncbi request reprint Statin therapy: new therapy for cardiac microvascular dysfunction
    Robert S Rosenson
    Eur Heart J 24:1993-4. 2003
  58. ncbi request reprint Cardiovascular disease prevention and care in Latino and Hispanic subjects
    Jaime A Davidson
    University of Texas Southwestern Medical School, Dallas, Texas, USA
    Endocr Pract 13:77-85. 2007
    ..To determine the scope, impact, and health care limitations relative to cardiovascular disease (CVD) in the Latino-Hispanic population...
  59. ncbi request reprint Statins: can the new generation make an impression?
    Robert S Rosenson
    Northwestern University, Preventive Cardiology Center, The Feinberg School of Medicine, 201 E Huron Street, Galter Pavilion, Suite 11 120, Chicago, IL 60611, USA
    Expert Opin Emerg Drugs 9:269-79. 2004
    ..Results of a number of outcome studies with rosuvastatin are expected over the next 5 years, which will contribute to the evidence base for statin therapy and cardiovascular disease prevention...